NewsBenzinga크리스퍼 테라퓨틱스, 일요일 발표···전신 경화증 환자의 83%가 주고-셀 투여 3개월 후 rCRISS-25 반응 달성, 근염 환자 9명 모두 중등도 또는 주요 TIS 반응 달성 크리스퍼 테라퓨틱스, 일요일 발표···전신 경화증 환자의 83%가 주고-셀 투여 3개월 후 rCRISS-25 반응 달성, 근염 환자 9명 모두 중등도 또는 주요 TIS 반응 달성 Benzinga 2026.11.09 08:11 (GMT+0) Open on Benzinga Other news Leerink Partners Initiates Coverage On Erasca with Outperform Rating, Announces Price Target of $35 What's Going on With AST SpaceMobile Stock on Monday? Reported November 16, U.S. CMS Issues Proposed Rule To Target Fraud Across Medicare, Medicaid/CHIP, And The Marketplace; Sees Possible Savings Of $90B Over Next 10 Years Stock of the Day: Is Pepsi About to Break Out? Intel Extends Slide as Nvidia Trims Stake 25%, Shareholder Suit Adds Pressure HC Wainwright & Co. Maintains Buy on Soluna Holdings, Lowers Price Target to $3
Reported November 16, U.S. CMS Issues Proposed Rule To Target Fraud Across Medicare, Medicaid/CHIP, And The Marketplace; Sees Possible Savings Of $90B Over Next 10 Years